Recruiting

PVE & HVEDRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

Sponsor:

Maastricht University Medical Center

Code:

NCT07717437

Conditions

Liver Cancer

Liver Metastases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This collaborative registry focuses on identifying associations between baseline clinical/imaging parameters, clinical outcomes, and safety for patients undergoing PVE/HVE.

Conditions

Liver Cancer

Liver Metastases

Study ID

NCT07717437

Start date

Mar 16, 2021

Status verified date

Jul, 2026

Completion date

Nov 30, 2032

Anticipated

Primary completion date

Nov 30, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Patients who have undergone PVE/HVE or technical variations on this procedure
18 Years and older
Men and women

Study Design

Enrollment

350 participants

Anticipated

Interventions and Outcome Measures

Arms

PVE/HVE

This registry collects data on patients who have undergone combined portal and hepatic vein embolisation prior to major liver surgery.

Primary outcome measure

Resectability three weeks after PVE/HVE and 5 years overall survival [ Time Frame: From enrolment until 5 year follow up ]

Central Contacts and Locations

Central contacts

Fenna Van der Zijden, Dr.

+316 40911632 fenna.van.der.zijden@mumc.nl

Locations

Rush University Medical Center

Recruiting

Chicago, Illinois, United States, 60612

Contacts

Frannie Richards

+1 312-942-5000 frannie_l_richards@rush.edu

Principal Investigator:

Matthew Dixon, Dr.

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Yawen Dong, Dr.

+1 507-284-2511 InternationalCollaborate@mayo.edu

Cleveland Clinic

Recruiting

Cleveland, Ohio, United States, 44195

Contacts

Federico Aucejo, Dr.

+1 216-444-2200 patientexperienceccl@ccf.org

Principal Investigator:

Federico Aucejo, Dr.

Juravinski Hospital and Cancer Centre

Recruiting

Hamilton, Ontario, Canada, L8V 5C2

Contacts

Elisabeth Lo

+1 905-387-9495 loe3@mcmaster.ca

Principal Investigator:

Leyo Ruo, Dr.

The Ottawa Hospital

Recruiting

Ottawa, Ontario, Canada, K1H 8L6

Contacts

Zanna Vanterpool

+1 613-722-7000 zvanterpool@ohri.ca

Principal Investigator:

Guillaume Martel, Dr.

McGill University Health Centre

Recruiting

Montreal, Quebec, Canada, H3G 1A4

Contacts

Jennifer Kalil

+1 514-934-1934 Jennifer.kalil@mail.mcgill.ca

Principal Investigator:

Peter Metrakos, Prof. Dr.

More Information

Sponsor

Maastricht University Medical Center

Last update posted

Jul 21, 2026

Last verified

Jul, 2026

Keywords

Liver cancer
Liver metastases
Portal vein embolization
PVE
HVE
PVE/HVE
Future liver remnant
Liver resection
Hepatectomy
Post-hepatectomy liver failure
Surgical oncology
Double Vein Embolisation
FLR
Liver Venous Deprivation
LVD
Hepatic Vein Embolization
Hepatocellular Carcinoma
Perihilar cholangiocarcinoma
Intrahepatic cholangiocarcinoma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Maastricht University Medical Center on 2026-07-21.